Update on the pathobiology of neuropathic pain

Expert Review of Proteomics

Volumn 5, Issue 6, 2008, Pages 799-818

  Niederberger, Ellen ^a   Kühlein, Hilmar ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Allodynia; Analgesics; Drug development; Hyperalgesia; Neuropathy; Sensitization

Indexed keywords

ANALGESIC AGENT; BIOLOGICAL MARKER;

CEREBROSPINAL FLUID ANALYSIS; HUMAN; NERVE COMPRESSION; NERVE DEGENERATION; NERVE INJURY; NERVE REGENERATION; NEUROMA; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SPINAL CORD INJURY;

ANIMALS; BIOLOGICAL MARKERS; BIOLOGY; DISEASE MODELS, ANIMAL; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEOMICS;

ANIMALIA;

EID: 58149148235     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.5.6.799     Document Type: Review

References (82)

1. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353(9168), 1959-1964 (1999).
2. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 73(2), 123-139 (1997).
3. Koltzenburg M. Painful neuropathies. Curr. Opin. Neurol. 11(5), 515-521 (1998).
4. Dray A. Neuropathic pain: emerging treatments. Br. J. Anaesth. 101(1), 48-58 (2008). • Overview of current knowledge on neuropathy mechanisms and new drug targets and developments.
5. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 52(1), 77-92 (2006).
6. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83(3), 389-400 (1999).
7. Hansson PT, Dickenson AH. Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 113(3), 251-254 (2005).
8. Chen H, Lamer TJ, Rho RH et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin. Proc. 79(12), 1533-1545 (2004).
9. Orth AP, Batalov S, Perrone M, Chanda SK. The promise of genomics to identify novel therapeutic targets. Expert Opin. Ther. Targets 8(6), 587-596 (2004).
10. Banks RE, Dunn MJ, Hochstrasser DF et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 356(9243), 1749-1756 (2000).
11. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 27(5), 251-259 (2006).
12. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell. Proteomics 3(5), 490-500 (2004).
13. Niederberger E, Geisslinger G. Proteomics in neuropathic pain research. Anesthesiology 108(2), 314-323 (2008).
14. Wang LX, Wang ZJ. Animal and cellular models of chronic pain. Adv. Drug Deliv. Rev. 55(8), 949-965 (2003). • Summary of a variety of important animal models.
15. Hu SJ, Xing JL. An experimental model for chronic compression of dorsal root ganglion produced by intervertebral foramen stenosis in the rat. Pain 77(1), 15-23 (1998).
16. Song XJ, Hu SJ, Greenquist KW, Zhang JM, LaMotte RH. Mechanical and thermal hyperalgesia and ectopic neuronal discharge after chronic compression of dorsal root ganglia. J. Neurophysiol. 82(6), 3347-3358 (1999).
17. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87(2), 149-158 (2000).
18. Rivera L, Gallar J, Pozo MA, Belmonte C. Responses of nerve fibres of the rat saphenous nerve neuroma to mechanical and chemical stimulation: an in vitro study. J. Physiol. 527 Pt 2, 305-313 (2000).
19. Huang HL, Cendan CM, Roza C et al. Proteomic profiling of neuromas reveals alterations in protein composition and local protein synthesis in hyper-excitable nerves. Mol. Pain 4(1), 33 (2008).
20. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50(3), 355-363 (1992).
21. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59(3), 369-376 (1994).
22. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43(2), 205-218 (1990).
23. Tahmoush AJ. Causalgia: redefinition as a clinical pain syndrome. Pain 10(2), 187-197 (1981).
24. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33(1), 87-107 (1988).
25. George A, Marziniak M, Schafers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-α, increases interleukin-10 and has long-term effects on spinal cord dorsal horn metenkephalin. Pain 88(3), 267-275 (2000).
26. Zimmermann M. Pathobiology of neuropathic pain. Eur. J. Pharmacol. 429(1-3), 23-37 (2001).
27. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum. Psychopharmacol. 19(Suppl. 1), S15-S19 (2004).
28. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-α expression. Pain 74(1), 35-42 (1998).
29. Jimenez CR, Stam FJ, Li KW et al. Proteomics of the injured rat sciatic nerve reveals protein expression dynamics during regeneration. Mol. Cell. Proteomics 4(2), 120-132 (2005).
30. Bester H, Beggs S, Woolf CJ. Changes in tactile stimuli-induced behavior and c-Fos expression in the superficial dorsal horn and in parabrachial nuclei after sciatic nerve crush. J. Comp. Neurol. 428(1), 45-61 (2000).
31. Greenberg J, McKeever PE, Balentine JD. Lysosomal activity in experimental spinal cord trauma: an ultrastructural cytochemical evaluation. Surg. Neurol. 9(6), 361-364 (1978).
32. Anderson TE. A controlled pneumatic technique for experimental spinal cord contusion. J. Neurosci. Methods 6(4), 327-333 (1982).
33. Tarlov IM. Acute spinal cord compression paralysis. J. Neurosurg. 36(1), 10-20 (1972).
34. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg. Neurol. 10(1), 38-43 (1978).
35. Watson BD, Prado R, Dietrich WD, Ginsberg MD, Green BA. Photochemically induced spinal cord injury in the rat. Brain Res. 367(1-2), 296-300 (1986).
36. Hao JX, Xu XJ, Aldskogius H, Seiger A, Wiesenfeld-Hallin Z. Photochemically induced transient spinal ischemia induces behavioral hypersensitivity to mechanical and cold stimuli, but not to noxious-heat stimuli, in the rat. Exp. Neurol. 118(2), 187-194 (1992).
37. Gorman AL, Yu CG, Ruenes GR, Daniels L, Yezierski RP. Conditions affecting the onset, severity, and progression of a spontaneous pain-like behavior after excitotoxic spinal cord injury. J. Pain 2(4), 229-240 (2001).
38. Wilcox GL. Pharmacological studies of grooming and scratching behavior elicited by spinal substance P and excitatory amino acids. Ann. NY Acad. Sci. 525, 228-236 (1988).
39. Christensen MD, Hulsebosch CE. Chronic central pain after spinal cord injury. J. Neurotrauma 14(8), 517-537 (1997).
40. Christensen MD, Everhart AW, Pickelman JT, Hulsebosch CE. Mechanical and thermal allodynia in chronic central pain following spinal cord injury. Pain 68(1), 97-107 (1996).
41. Bennett AD, Chastain KM, Hulsebosch CE. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain 86(1-2), 163-175 (2000).
42. Ding Q, Wu Z, Guo Y et al. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. Proteomics 6(2), 505-518 (2006).
43. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250(10), 4007-4021 (1975).
44. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal. Biochem. 203(1), 173-179 (1992).
45. Burre J, Beckhaus T, Corvey C et al. Synaptic vesicle proteins under conditions of rest and activation: analysis by 2-D difference gel electrophoresis. Electrophoresis 27(17), 3488-3496 (2006).
46. Matsumoto H, Komori N. Protein identification on two-dimensional gels archived nearly two decades ago by in-gel digestion and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal. Biochem. 270(1), 176-179 (1999).
47. Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp. Brain Res. 113(2), 200-206 (1997).
48. Lee DH, Chung K, Chung JM. Strain differences in adrenergic sensitivity of neuropathic pain behaviors in an experimental rat model. Neuroreport 8(16), 3453-3456 (1997).
49. Zhang Y, Wang YH, Zhang XH et al. Proteomic analysis of differential proteins related to the neuropathic pain and neuroprotection in the dorsal root ganglion following its chronic compression in rats. Exp. Brain Res. (2008).
50. Lee SC, Yoon TG, Yoo YI et al. Analysis of spinal cord proteome in the rats with mechanical allodynia after the spinal nerve injury. Biotechnol. Lett. 25(24), 2071-2078 (2003).
51. Alzate O, Hussain SR, Goettl VM et al. Proteomic identification of brainstem cytosolic proteins in a neuropathic pain model. Brain Res. Mol. Brain Res. 128(2), 193-200 (2004).
52. Komori N, Takemori N, Kim HK et al. Proteomics study of neuropathic and nonneuropathic dorsal root ganglia: altered protein regulation following segmental spinal nerve ligation injury. Physiol. Genomics 29(2), 215-230 (2007).
53. Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48(5), 723-729 (2000).
54. Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5(3), 347-350 (1999).
55. Xu CJ, Klunk WE, Kanfer JN et al. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with atp-dependent glutamate uptake. J. Biol. Chem. 271(23), 13435-13440 (1996).
56. Arimura N, Menager C, Fukata Y, Kaibuchi K. Role of CRMP-2 in neuronal polarity. J. Neurobiol. 58(1), 34-47 (2004).
57. Katano T, Mabuchi T, Okuda-Ashitaka E et al. Proteomic identification of a novel isoform of collapsin response mediator protein-2 in spinal nerves peripheral to dorsal root ganglia. Proteomics 6(22), 6085-6094 (2006).
58. Kunz S, Tegeder I, Coste O et al. Comparative proteomic analysis of the rat spinal cord in inflammatory and neuropathic pain models. Neurosci. Lett. 381(3), 289-293 (2005).
59. Beattie MS, Farooqui AA, Bresnahan JC. Review of current evidence for apoptosis after spinal cord injury. J. Neurotrauma 17(10), 915-925 (2000).
60. Profyris C, Cheema SS, Zang D et al. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis. 15(3), 415-436 (2004).
61. Kang SK, So HH, Moon YS, Kim CH. Proteomic analysis of injured spinal cord tissue proteins using 2-DE and MALDI-TOF MS. Proteomics 6(9), 2797-2812 (2006).
62. Conti A, Ricchiuto P, Iannaccone S et al. Pigment epithelium-derived factor is differentially expressed in peripheral neuropathies. Proteomics 5(17), 4558-4567 (2005). • One of the first studies that investigated protein modifications in human neuropathies.
63. Pasinetti GM, Ungar LH, Lange DJ et al. Identification of potential CSF biomarkers in ALS. Neurology 66(8), 1218-1222 (2006).
64. D'Aguanno S, Barassi A, Lupisella S et al. Differential cerebrospinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. J. Neuroimmunol. 193(1-2), 156-160 (2008).
65. Costigan M, Befort K, Karchewski L et al. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci. 3, 16 (2002). • Genomic study that shows some overlapping regulations with the proteomic studies.
66. Fu SY, Gordon T. The cellular and molecular basis of peripheral nerve regeneration. Mol. Neurobiol. 14(1-2), 67-116 (1997).
67. Fournier AE, McKerracher L. Expression of specific tubulin isotypes increases during regeneration of injured CNS neurons, but not after the application of brain-derived neurotrophic factor (BDNF). J. Neurosci. 17(12), 4623-4632 (1997).
68. Baldwin SA, Broderick R, Blades DA, Scheff SW. Alterations in temporal/spatial distribution of GFAP- and vimentin-positive astrocytes after spinal cord contusion with the New York University spinal cord injury device. J. Neurotrauma 15(12), 1015-1026 (1998).
69. Willis D, Li KW, Zheng JQ et al. Differential transport and local translation of cytoskeletal, injury-response, and neurodegeneration protein mRNAs in axons. J. Neurosci. 25(4), 778-791 (2005).
70. Perlson E, Hanz S, Ben-Yaakov K et al. Vimentin-dependent spatial translocation of an activated MAP kinase in injured nerve. Neuron 45(5), 715-726 (2005).
71. Sharma HS, Gordh T, Wiklund L, Mohanty S, Sjoquist PO. Spinal cord injury induced heat-shock protein expression is reduced by an antioxidant compound H-290/51. An experimental study using light and electron microscopy in the rat. J. Neural Transm. 113(4), 521-536 (2006). • Demonstrates the correlation of heatshock proteins and nerve injury.
72. Yenari MA, Giffard RG, Sapolsky RM, Steinberg GK. The neuroprotective potential of heat-shock protein 70 (HSP70). Mol. Med. Today 5(12), 525-531 (1999).
73. Costigan M, Mannion RJ, Kendall G et al. Heat-shock protein 27: developmental regulation and expression after peripheral nerve injury. J. Neurosci. 18(15), 5891-5900 (1998).
74. Kretz A, Schmeer C, Tausch S, Isenmann S. Simvastatin promotes heat-shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol. Dis. 21(2), 421-430 (2006).
75. Latchman DS. HSP27 and cell survival in neurones. Int. J. Hyperthermia 21(5), 393-402 (2005).
76. Weber CA, Ernst ME. Antioxidants, supplements, and Parkinson's disease. Ann. Pharmacother. 40(5), 935-938 (2006).
77. Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: part 2. Ann. Pharmacother. 39(12), 2065-2072 (2005).
78. Hinault MP, Ben-Zvi A, Goloubinoff P. Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging. J. Mol. Neurosci. 30(3), 249-265 (2006).
79. Obata K, Yamanaka H, Kobayashi K et al. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J. Neurosci. 24(45), 10211-10222 (2004).
80. Mao J, Price DD, Mayer DJ, Hayes RL. Pain-related increases in spinal cord membrane-bound protein kinase C following peripheral nerve injury. Brain Res. 588(1), 144-149 (1992).
81. Scholz J, Woolf CJ. Can we conquer pain? Nat. Neurosci. 5(Suppl.), 1062-1067 (2002). • Discussion of treatment strategies for pain of different qualities.
82. Beyreuther BK, Freitag J, Heers C et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13(1), 21-42 (2007).